Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
4.1. Commonly Used Genetic Engineering Techniques
4.2. Commonly Used Gene Editing Techniques
4.3. Benefits of Using Genetic Engineering Tools
4.4. Preference for Genetic Engineering Tools, By Therapeutic Area
4.5. Barriers to Adoption of Genetic Engineering Tools
4.6. Brand Awareness
5. Global Genetic Engineering Tools Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
5.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
5.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
5.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer’s Disease, Obesity, Others)
5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
5.2.4. By Company (2022)
5.2.5. By Region
5.3. Market Map
5.3.1. By Type
5.3.2. By Therapeutic Area
5.3.3. By End User
5.3.4. By Region
6. North America Genetic Engineering Tools Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
6.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
6.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
6.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer’s Disease, Obesity, Others)
6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Genetic Engineering Tools Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Therapeutic Area
6.3.1.2.3. By End User
6.3.2. Mexico Genetic Engineering Tools Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Therapeutic Area
6.3.2.2.3. By End User
6.3.3. Canada Genetic Engineering Tools Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Therapeutic Area
6.3.3.2.3. By End User
7. Europe Genetic Engineering Tools Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
7.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
7.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
7.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer’s Disease, Obesity, Others)
7.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Genetic Engineering Tools Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Therapeutic Area
7.3.1.2.3. By End User
7.3.2. Germany Genetic Engineering Tools Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Therapeutic Area
7.3.2.2.3. By End User
7.3.3. United Kingdom Genetic Engineering Tools Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Therapeutic Area
7.3.3.2.3. By End User
7.3.4. Italy Genetic Engineering Tools Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Therapeutic Area
7.3.4.2.3. By End User
7.3.5. Spain Genetic Engineering Tools Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Therapeutic Area
7.3.5.2.3. By End User
8. Asia-Pacific Genetic Engineering Tools Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
8.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
8.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
8.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer’s Disease, Obesity, Others)
8.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Genetic Engineering Tools Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Therapeutic Area
8.3.1.2.3. By End User
8.3.2. India Genetic Engineering Tools Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Therapeutic Area
8.3.2.2.3. By End User
8.3.3. South Korea Genetic Engineering Tools Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Therapeutic Area
8.3.3.2.3. By End User
8.3.4. Japan Genetic Engineering Tools Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Therapeutic Area
8.3.4.2.3. By End User
8.3.5. Australia Genetic Engineering Tools Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Therapeutic Area
8.3.5.2.3. By End User
8.3.6. Thailand Genetic Engineering Tools Market Outlook
8.3.6.1. Market Size & Forecast
8.3.6.1.1. By Value
8.3.6.2. Market Share & Forecast
8.3.6.2.1. By Type
8.3.6.2.2. By Therapeutic Area
8.3.6.2.3. By End User
8.3.7. Singapore Genetic Engineering Tools Market Outlook
8.3.7.1. Market Size & Forecast
8.3.7.1.1. By Value
8.3.7.2. Market Share & Forecast
8.3.7.2.1. By Type
8.3.7.2.2. By Therapeutic Area
8.3.7.2.3. By End User
9. South America Genetic Engineering Tools Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
9.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
9.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
9.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer’s Disease, Obesity, Others)
9.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Genetic Engineering Tools Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Therapeutic Area
9.3.1.2.3. By End User
9.3.2. Argentina Genetic Engineering Tools Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Therapeutic Area
9.3.2.2.3. By End User
9.3.3. Colombia Genetic Engineering Tools Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Therapeutic Area
9.3.3.2.3. By End User
10. Middle East and Africa Genetic Engineering Tools Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
10.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
10.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
10.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer’s Disease, Obesity, Others)
10.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Genetic Engineering Tools Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Therapeutic Area
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Genetic Engineering Tools Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Therapeutic Area
10.3.2.2.3. By End User
10.3.3. UAE Genetic Engineering Tools Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Therapeutic Area
10.3.3.2.3. By End User
10.3.4. Israel Genetic Engineering Tools Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Type
10.3.4.2.2. By Therapeutic Area
10.3.4.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Genetic Engineering Tool Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Financials (As Reported)
15.5. Key Personnel
15.6. SWOT Analysis
15.6.1. Thermo Fisher Scientific Inc
15.6.2. CRISPR Therapeutics AG
15.6.3. Editas Medicine, Inc.
15.6.4. Intellia Therapeutics, Inc
15.6.5. Merck KGaA
15.6.6. Horizon Discovery Ltd
15.6.7. GeneCopoeia Inc
15.6.8. Takara Bio Inc
15.6.9. Sangamo Therapeutics, Inc.
15.6.10. Genscript Biotech Corporation
16. Strategic Recommendations